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LETTERS TO THE EDITOR
Pulmonary Vasoreactivity in PPH
We read with interest the article by Krasuski et al. (1) titled
“Inhaled Nitric Oxide Selectively Dilates Pulmonary Vasculature
in Adult Patients With Pulmonary Hypertension, Irrespective of
Etiology.” The investigators reported that 67% of patients with
primary pulmonary hypertension (PPH) and 63% of patients with
secondary pulmonary hypertension had a decrease in mean pul-
monary artery pressure (mPAP) of at least 20% with acute testing
using inhaled nitric oxide (iNO). In contrast, the acute response
rates from our institutions are much lower. Over the last year, a
total of 97 adult patients with PPH were tested at our three
centers. Using the same criteria as Krasuski et al. (1) to define a
positive vasodilator response, we observed an overall acute response
rate of only 21%. The response rate varied among institutions,
ranging from 13% to 35% in the adult population. We list the
number and percent with an acute response and the range of
positive responses in Table 1. Although we observed a higher acute
response rate in children with PPH (57%, n 5 30), children are
known to exhibit more pulmonary vasoreactivity than are adults
(2); Krasuski et al. (1) limited their study to adults, and the
youngest patient in their study was 26 years old.
Previous studies also support a lower acute response rate with
iNO. Sitbon et al. (3) tested 33 patients with PPH with inhaled
iNO (10 ppm) and found that only 10 (30%) had a decrease in
mPAP of 20% or more. More recently, Ricciardi et al. (4) studied
17 patients with PPH and found only 2 (12%) patients had a
decrease in mPAP of 20% or more with iNO (80 ppm). We are
concerned that the results reported from Krasuski et al. (1) may
provide misleading information to your readers and may result in
empiric treatment with chronic calcium channel-blocker therapy
without prior acute vasodilator testing.
Why the discrepancy between our findings and those of Kra-
suski et al. (1)? The reasons are unclear. All three of our
institutions use iNO at a concentration of $40 ppm, similar to the
concentration that Krasuski et al. (1) used in their study. Our
patients received iNO using a face mask in conjunction with
INOvent Delivery System (INO Therapeutics, Clinton, New
Jersey), as was used by Krasuski et al. (1) study, or a pulsed delivery
system (Devillbis Pulsair OMS 50, Cryo-Fab, Kenilworth, New
Jersey) via nasal cannula, which has previously been shown to
produce the same degree of vasodilation as that obtained with a
face mask (5). Krasuski et al. (1) administered nitric oxide for
5 min before hemodynamic measurements were obtained, not
significantly different from our protocols (range 5 to 10 min).
Hemodynamic instability during the course of the catheteriza-
tion may account for some of the difference between ourselves and
Krasuski et al. (1). The investigators do not appear to have
repeated baseline hemodynamics in-between different doses of
iNO, although the mPAP was very similar using 10, 20 or 40 ppm
of iNO, suggesting that hemodynamic instability was not a major
factor contributing to their results.
Despite the fact that the investigators’ cohort represents the largest
published study of acute testing with iNO in the adult population,
only 18 patients had PPH. It is possible that their high percentage of
acute responders is the result of a chance sampling of a group of
patients with a higher rate of vasoreactivity than expected. This seems
unlikely, however, as Duke is a large referral center, as are our
institutions, so that one would expect sicker patients with a lower than
expected rate of acute vasoreactivity to be seen there.
It is clear that large numbers of patients need to be evaluated
with a standard protocol to obtain reproducible data. Presently,
there is still no consensus among investigators as to what consti-
tutes a positive acute response. Plans are underway for a multi-
center study to evaluate the acute effects of iNO and to compare
the results to those obtained with other agents used for acute
vasodilator testing. A more important question remains unan-
swered: How well does a positive response to acute vasodilator
testing predict long-term benefit with calcium channel-blocker
therapy? Before answering that question, however, we need to be
sure that we have reliably tested patients for pulmonary vasoreac-
tivity. We strongly caution against empiric treatment with calcium
channel blockers based on the assumption that most PPH patients
are vasoreactive.
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Table 1. Acute Response Rate and Range of Positive Responses
Among Institutions
No.
Acute
Vasodilator
Responders,
No. (%)
Range of %
Decrease in
mPAP
in Acute
Responders
Vanderbilt 27 7 (26) 22–35
Columbia 20 7 (35) 20–63
UCSD 48 6 (13) 20–50
mPAP 5 mean pulmonary artery pressure; UCSD 5 University of California, San
Deigo.
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